ZYLOXTB (02190) rose nearly 7% during the trading session. As of the time of writing, the stock was up 5.65%, trading at HK$25.04, with a turnover of HK$17.88 million.

The surge follows the company's recent issuance of a positive profit alert.

ZYLOXTB anticipates its full-year 2025 net profit will exceed RMB 240 million, representing a substantial increase of approximately 139.4% compared to the same period last year.

Furthermore, the company expects its operating revenue to surpass RMB 1.05 billion, marking a year-on-year growth of about 34.6%.

The company attributed its strong 2025 performance primarily to robust growth in core product sales, accelerated development of its overseas operations, and continuous optimization of operational efficiency.

During the reporting period, products such as the Tongqiao Qilin Blood Flow Diverter, neurovascular guidewires, the UltraFree Drug-Eluting PTA Balloon Dilatation Catheter, and the ZYLOX Swan Venous Intraluminal Radiofrequency Ablation Catheter all achieved rapid sales growth.

In terms of international business, the company's overseas market sales revenue increased by over 100% year-on-year, with its market penetration continuing to rise in key countries such as Germany, France, and Italy.

Concurrently, the company achieved a critical breakthrough in its internationalization strategy, leading to a comprehensive acceleration in its overseas market expansion.